

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	4	AUG 11	STN AnaVist workshops to be held in North America
NEWS	5	AUG 30	CA/Caplus -Increased access to 19th century research documents
NEWS	6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS	7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	8	OCT 03	MATHDI removed from STN
NEWS	9	OCT 04	CA/Caplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	10	OCT 06	STN AnaVist workshops to be held in North America
NEWS	11	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	12	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of Caplus documents for use in third-party analysis and visualization tools
NEWS EXPRESS		JUNE 13	CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:45:31 ON 24 OCT 2005

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 08:46:05 ON 24 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0

DICTIONARY FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10626356.str



0

5

1

1

chain nodes :

1 2 3 4 5 8 9 10

```

ring nodes :
15 16 17 18 19
chain bonds :
1-3 3-8 4-5 8-9 9-10
ring bonds :
15-16 15-19 16-17 17-18 18-19
exact/norm bonds :
1-3 3-8 4-5 8-9 9-10 15-16 15-19 16-17 17-18 18-19

```

G2:SO2,[*1]

```

Match level :
1:Atom 2:Atom 3:CLASS 4:CLASS 5:CLASS 8:CLASS 9:CLASS 10:Atom 15:Atom
16:Atom 17:Atom 18:Atom 19:Atom 20:CLASS 21:CLASS

```

Generic attributes :

```

1:
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System    : Monocyclic

```

Element Count :

Node 1: Limited

N,N1

O,O0

S,S0


C,C4

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:46:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 9711 TO ITERATE

20.6% PROCESSED 2000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

3 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 188315 TO 200125

PROJECTED ANSWERS: 63 TO 519


L2 3 SEA SSS SAM L1

```
=> s l1 full
FULL SEARCH INITIATED 08:46:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 192018 TO ITERATE
```

```
100.0% PROCESSED 192018 ITERATIONS 377 ANSWERS
SEARCH TIME: 00.00.02
```

```
L3 377 SEA SSS FUL L1
```

```
=> s l3 and caplus/lc
48312124 CAPLUS/LC
L4 368 L3 AND CAPLUS/LC
```



```
0 5
1 1
```

```
chain nodes :
1 2 3 4 5 8 9 10
ring nodes :
15 16 17 18 19
chain bonds :
1-3 3-8 4-5 8-9 9-10
ring bonds :
15-16 15-19 16-17 17-18 18-19
exact/norm bonds :
1-3 3-8 4-5 8-9 9-10 15-16 15-19 16-17 17-18 18-19
```

```
G2:SO2, [*1]
```

```
Match level :
1:Atom 2:Atom 3:CLASS 4:CLASS 5:CLASS 8:CLASS 9:CLASS 10:Atom 15:Atom
16:Atom 17:Atom 18:Atom 19:Atom 20:CLASS 21:CLASS
Generic attributes :
1:
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic
```


```
Element Count :
Node 1: Limited
N,N1
O,O0
S,S0
C,C4
```

L5 STRUCTURE UPLOADED

=> d

L5 HAS NO ANSWERS

L5 STR



O

1

G1

G2 SO2, [01]

Structure attributes must be viewed using STN Express query preparation.

=> s l5 subset=l3 full

FULL SUBSET SEARCH INITIATED 08:52:42 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 300 TO ITERATE

100.0% PROCESSED 300 ITERATIONS

173 ANSWERS

SEARCH TIME: 00.00.01

L6 173 SEA SUB=L3 SSS FUL L5

=> s l6 and caplus/lc

48312124 CAPLUS/LC

L7 173 L6 AND CAPLUS/LC

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

213.31

213.52

FILE 'CAPLUS' ENTERED AT 08:52:59 ON 24 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Oct 2005 VOL 143 ISS 18
FILE LAST UPDATED: 23 Oct 2005 (20051023/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 17


L8 3 L7

=> d ibib abs hitstr 1-3

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:158664 CAPLUS
DOCUMENT NUMBER: 142:261539
TITLE: Preparation of pyrrole-containing heterocyclic compounds as inhibitors of c-Met
INVENTOR(S): Aronov, Alex; Bandarage, Upul K.; Lauffer, David J.
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA; Li, Pan; Tomlinson, Ronald C.
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016920	A1	20050224	WO 2004-US26749	20040816
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005101650	A1	20050512	US 2004-919774	20040816
PRIORITY APPLN. INFO.:			US 2003-495535P	P 20030815
OTHER SOURCE(S): MARPAT 142:261539				
GI				




AB The title compds. I [Q is an alkylidene chain wherein one methylene unit of Q is replaced by CO, O, etc.; R1 = H, optionally substituted ring, etc.; R2 = optionally substituted 6-membered aryl ring having 0 - 5 nitrogens; n = 0 - 2; ring A = imidazole ring, etc.; R3 = CN, etc.] are prepared. Thus, 4-[5-(2,3-difluorophenyl)isoxazol-4-yl]-1H-pyrrole-2-carboxylic acid (S-tetrahydrofuran-2-ylmethyl)amide was prepared in a multistep process from 1-(1-benzenesulfonyl-1H-pyrrol-3-yl)ethanone. In an in vitro test for the inhibition of c-Met kinase, compds. of this invention showed Ki values of 1 to > 10 μ M.

IT 845867-57-4P 845867-58-5P 845867-59-6P 845867-61-0P 845867-62-1P 845867-63-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 845867-62-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-[3-(2,3-difluorophenyl)-4-isoxazolyl]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 845867-63-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
N-(cyclopentylmethyl)-4-[3-(2,3-difluorophenyl)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

(Uses)
(prepn. of pyrrole-contg. heterocyclic compds. as inhibitors of c-Met)
RN 845867-57-4 CAPLUS
CN Azetidine, 1-[[4-(5-(2,3-difluorophenyl)-4-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 845867-58-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-[5-(2,3-difluorophenyl)-4-isoxazolyl]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 845867-59-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-[5-(2,3-difluorophenyl)-4-isoxazolyl]-N-[(2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845867-61-0 CAPLUS
CN Pyrrolidine, 1-[[4-(3-(2,3-difluorophenyl)-4-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 2003:906502 CAPLUS
DOCUMENT NUMBER: 140:111220
TITLE: Solid-Phase Synthesis of an Isoxazolinopyrrole
LIBRARY:
AUTHOR(S): Hwang, Sung Hee; Olmstead, Marilyn M.; Kurth, Mark J.
CORPORATE SOURCE: Department of Chemistry, University of California, Davis, CA, 95616-5295, USA
SOURCE: Journal of Combinatorial Chemistry (2004), 6(1), 142-148
CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:111220
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB A four-step solid-phase synthesis of isoxazolinopyrroles, e.g., I, that employs an acid-labile 2-(4-formyl-3-methoxyphenoxy)ethyl polystyrene HL resin is reported. Resin-bound vinyl sulfone II (R1 = PhCH2, 2-furanylmethyl, Me2CHCH2, MeOCH2CH2; X = resin) is obtained by DIC coupling of resin-bound amines with acid III (R2 = H, Me), which was in turn synthesized in solution phase by a regioselective nitrile oxide, 1,3-dipolar cycloaddn. The resin-bound pyrrole, e.g., IV, was synthesized on solid phase by pyrrole annulation with various isocyanate derivs. and potassium t-butoxide in which the sulfone α -anion generated by Michael addition gives the desired pyrrole through internal condensation followed by a sigmatropic [1,5]-hydrogen shift. The resulting isoxazolinopyrroles were released from resin by 10% TFA in moderate to excellent overall yields.

IT 646064-11-1P 646064-12-2P 646064-13-3P 646064-14-4P 646064-18-8P 646064-19-9P 646064-20-2P 646064-21-3P 646064-22-4P 646064-23-5P 646064-24-6P 646064-25-7P
RL: CPH (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(preparation of an isoxazolinopyrrole library via coupling of resin-bound amines with sulfonylvinylisoxazolyl benzoic acids followed by pyrrole annulation with various isocyanate derivs. and subsequent cleavage from the resin)


RN 646064-11-1 CAPLUS
CN Benzamide,
4-(4,5-dihydro-5-methyl-5-(4-(phenylsulfonyl)-1H-pyrrol-3-yl)-3-isoxazolyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 646064-12-2 CAPLUS
CN Benzamide,
4-[(4,5-dihydro-5-methyl-5-[(4-(phenylsulfonyl)-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(2-furanylmethyl))- (9CI) (CA INDEX NAME)]




RN 646064-13-3 CAPLUS
CN Benzamide,
4-[(4,5-dihydro-5-methyl-5-[(4-(phenylsulfonyl)-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(2-methylpropyl))- (9CI) (CA INDEX NAME)]




RN 646064-14-4 CAPLUS
CN Benzamide,
4-[(4,5-dihydro-5-methyl-5-[(4-(phenylsulfonyl)-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(2-methoxyethyl))- (9CI) (CA INDEX NAME)]




RN 646064-21-3 CAPLUS
CN Benzamide, 4-[(4,5-dihydro-5-methyl-5-[(4-methyl-2-(1-piperidinylcarbonyl)-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(2-methoxyethyl))- (9CI) (CA INDEX NAME)]




RN 646064-22-4 CAPLUS
CN Benzamide, 4-[(4,5-dihydro-5-methyl-5-[(4-methyl-2-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(phenylmethyl))- (9CI) (CA INDEX NAME)]




RN 646064-18-8 CAPLUS
CN Benzamide, 4-[(4,5-dihydro-5-methyl-5-[(4-methyl-2-(1-piperidinylcarbonyl)-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(phenylmethyl))- (9CI) (CA INDEX NAME)]




RN 646064-19-9 CAPLUS
CN Benzamide, 4-[(4,5-dihydro-5-methyl-5-[(4-methyl-2-(1-piperidinylcarbonyl)-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(2-furanylmethyl))- (9CI) (CA INDEX NAME)]




RN 646064-20-2 CAPLUS
CN Benzamide, 4-[(4,5-dihydro-5-methyl-5-[(4-methyl-2-(1-piperidinylcarbonyl)-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(2-methylpropyl))- (9CI) (CA INDEX NAME)]




RN 646064-23-5 CAPLUS
CN Benzamide, 4-[(4,5-dihydro-5-methyl-5-[(4-methyl-2-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(2-furanylmethyl))- (9CI) (CA INDEX NAME)]



RN 646064-24-6 CAPLUS
CN Benzamide, 4-[(4,5-dihydro-5-methyl-5-[(4-methyl-2-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl)-3-isoxazolyl]-N-(2-methylpropyl))- (9CI) (CA INDEX NAME)]



RN 646064-25-7 CAPLUS
 CN Benzamide, 4-[4,5-dihydro-5-methyl-5-[4-methyl-2-[(4-methylphenyl)sulfonyl]-1H-pyrrol-3-yl]-3-isoxazolyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

ACCESSION NUMBER: 2002:220586 CAPLUS
 DOCUMENT NUMBER: 136:247569
 TITLE: Preparation of isoxazolylpyrrole-2-carboxamides as ERK and AKT protein kinase inhibitors
 INVENTOR(S): Hale, Michael; Janetka, James; Maltais, Francois; Cao, Jingrong; Mashal, Robert
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 83 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022610	A1	20020321	WO 2001-US28790	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, CN, CO, GQ, GW, HL, HR, NE, SN, TD, TG				
CA 2422376	A5	20020321	CA 2001-2422376	20010914
AU 2001090940	A5	20020326	AU 2001-90940	20010914
US 2002177618	A1	20021128	US 2001-953120	20010914
US 6495582	B2	20021217		
EP 1317453	A1	20030611	EP 2001-971002	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, TE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509119	T2	20040325	JP 2002-526863	20010914
ZA 200301696	A	20040428	ZA 2003-1696	20010914
NZ 525016	A	20041029	NZ 2001-525016	20010914
US 2003195241	A1	20031016	US 2002-272622	20021015
US 6649640	B2	20031118		
NO 2003001192	A	20030513	NO 2003-1192	20030314
US 2005090536	A1	20050428	US 2003-626356	20030724
PRIORITY APPLN. INFO.:				P 20000915
				US 2001-953120 A3 20010914
				WO 2001-US28790 W 20010914


OTHER SOURCE(S): MARPAT 136:247569
 AB Title compds., e.g., Ph21Z2CONMe2 (Z1 = isoxazole-4,5-diyl, Z2 = pyrrole-4,2-diyl) were prepared Data for biol. activity of title compds. were given.
 IT 404570-75-8P 404570-76-9P 404570-77-0P 404570-78-1P 404570-80-3P 404570-81-6P 404570-82-7P 404570-83-8P 404570-84-9P 404570-85-0P 404570-86-1P 404570-87-2P 404570-88-3P 404570-89-4P 404570-90-7P 404570-91-8P 404570-92-9P 404570-93-0P 404570-94-1P 404570-95-2P 404570-96-3P 404570-97-4P 404570-98-5P

404570-99-6P 404571-00-2P 404571-01-3P 404571-02-4P 404571-03-5P 404571-04-6P 404571-05-7P 404571-06-8P 404571-07-9P 404571-08-0P 404571-09-1P 404571-10-4P 404571-11-5P 404571-12-6P 404571-13-7P 404571-14-8P 404571-15-9P 404571-16-0P 404571-17-1P 404571-18-2P 404571-19-3P 404571-20-6P 404571-21-7P 404571-22-8P 404571-23-9P 404571-24-0P 404571-25-1P 404571-26-2P 404571-27-3P 404571-28-4P 404571-29-5P 404571-30-6P 404571-31-9P 404571-32-0P 404571-33-1P 404571-34-2P 404571-35-3P 404571-36-4P 404571-37-5P 404571-38-6P 404571-39-7P 404571-40-0P 404571-41-1P 404571-42-2P 404571-43-3P 404571-44-4P 404571-45-5P 404571-46-6P 404571-53-5P 404571-54-6P 404571-55-7P 404571-56-8P 404571-57-9P 404571-58-0P 404571-59-1P 404571-60-4P 404571-61-5P 404571-62-6P 404571-63-7P 404571-64-8P 404571-65-9P 404571-66-0P 404571-67-1P 404571-68-2P 404571-69-3P 404571-70-6P 404571-71-7P 404571-72-8P 404571-73-9P 404571-74-0P 404571-75-1P 404571-76-2P 404571-77-3P 404571-78-4P 404571-79-5P 404571-80-8P 404571-81-9P 404571-82-0P 404571-83-1P 404571-84-2P 404571-85-3P 404571-86-4P 404571-87-5P 404571-88-6P 404571-89-7P 404571-90-0P 404571-91-1P 404571-92-2P 404571-93-3P 404571-95-5P 404571-96-6P 404571-97-7P 404571-98-8P 404571-99-9P 404572-00-5P 404572-01-6P 404572-02-7P 404572-03-8P 404572-04-9P 404572-05-0P 404572-06-1P 404572-07-2P 404572-08-3P 404572-09-4P 404572-10-7P 404572-11-8P 404572-12-9P 404572-13-0P 404572-14-1P 404572-15-2P 404572-16-3P 404572-17-4P 404572-18-5P 404572-20-9P 404572-21-0P 404572-22-1P 404572-23-2P 404572-24-3P 404572-25-4P 404572-26-5P 404572-28-7P 404572-29-8P 404572-30-1P 404572-31-2P 404572-32-3P 404572-33-4P 404572-35-6P 404572-36-7P 404572-38-9P 404572-39-0P 404572-40-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of isoxazolylpyrrole-2-carboxamides as ERK and AKT protein kinase inhibitors)


RN 404570-75-8 CAPLUS
 CN Morpholine, 4-[[4-[(2-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404570-76-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(4-methoxyphenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-77-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-fluorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-78-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-methoxyphenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 404570-79-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-dimethoxyphenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 404570-80-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-difluorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-81-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,3-difluorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-82-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-difluorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 404570-86-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-difluorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-87-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,3-difluorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-88-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-difluorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 404570-83-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(4-methoxyphenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-84-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-fluorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404570-85-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-methoxyphenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 404570-89-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(4-methoxyphenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404570-90-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-fluorophenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404570-91-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[4-(3-methoxyphenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404570-92-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-difluorophenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404570-93-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,3-difluorophenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404570-94-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-difluorophenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404570-98-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[4-(3-methoxyphenyl)-5-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 404570-99-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-dimethoxyphenyl)-5-isoxazolyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-00-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-difluorophenyl)-5-isoxazolyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404570-95-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[4-(4-fluorophenyl)-5-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 404570-96-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[4-(4-methoxyphenyl)-5-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 404570-97-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[4-(3-fluorophenyl)-5-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 404571-01-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,3-difluorophenyl)-5-isoxazolyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-02-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(2,5-difluorophenyl)-5-isoxazolyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-03-5 CAPLUS
CN Morpholine, 4-[4-(3-methoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl[carbonyl]- (9CI) (CA INDEX NAME)





RN 404571-04-6 CAPLUS
CN Morpholine, 4-[[4-[(2,5-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-05-7 CAPLUS
CN Morpholine, 4-[[4-[(2,3-difluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-06-8 CAPLUS
CN Morpholine, 4-[[4-[(2,5-difluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404571-11-5 CAPLUS
CN Piperazine, 1-[[4-[(2,5-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-12-6 CAPLUS
CN Piperazine, 1-[[4-[(2,3-difluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-13-7 CAPLUS
CN Piperazine, 1-[[4-[(2,5-difluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


RN 404571-07-9 CAPLUS
CN Piperazine, 1-[[4-[(4-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-08-0 CAPLUS
CN Piperazine, 1-[[4-[(4-methoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-09-1 CAPLUS
CN Piperazine, 1-[[4-[(3-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-10-4 CAPLUS
CN Piperazine, 1-[[4-[(3-methoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-14-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(3-chlorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-15-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(3-chlorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-16-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(3-chlorophenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-17-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-[(4-(3-chlorophenyl)-5-isoxazolyl)-N-[(1-ethyl-
2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-18-2 CAPLUS
CN Piperazine, 1-[[4-(4-(3-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-
yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-19-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(4-chlorophenyl)-5-isoxazolyl)-N-[(1-ethyl-
2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-20-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(4-chlorophenyl)-5-isoxazolyl)-N-[(3-
pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-21-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(4-chlorophenyl)-5-isoxazolyl)-N-
[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-22-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
4-[(4-(4-chlorophenyl)-5-isoxazolyl)-N-[(1-ethyl-
2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-23-9 CAPLUS
CN Morpholine, 4-[[4-(4-(4-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-
yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-24-0 CAPLUS
CN Piperazine, 1-[[4-(4-(4-chlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-
yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-25-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3,4-dichlorophenyl)-5-isoxazolyl)-N-[(3-
pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-26-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3,4-dichlorophenyl)-5-isoxazolyl)-N-[(1-
ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-27-3 CAPLUS
CN Morpholine, 4-[[4-(4-(3,4-dichlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-
yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-28-4 CAPLUS
CN Piperazine, 1-[[4-(4-(3,4-dichlorophenyl)-5-isoxazolyl)-1H-pyrrol-2-
yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-29-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-N-(4-pyridinylmethyl)]- (9CI) (CA INDEX NAME)




RN 404571-30-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-N-(3-pyridinylmethyl)]- (9CI) (CA INDEX NAME)




RN 404571-31-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-N-(4-pyridinylmethyl)]- (9CI) (CA INDEX NAME)




RN 404571-35-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chloro-4-fluorophenyl)-5-isoxazolyl)-N-(4-pyridinylmethyl)]- (9CI) (CA INDEX NAME)




RN 404571-36-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chloro-4-fluorophenyl)-5-isoxazolyl)-N-(3-pyridinylmethyl)]- (9CI) (CA INDEX NAME)




RN 404571-37-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chloro-4-fluorophenyl)-5-isoxazolyl)-N-([tetrahydro-2-furanyl]methyl)]- (9CI) (CA INDEX NAME)




RN 404571-32-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-N-([1-ethyl-2-pyrrolidinyl]methyl)]- (9CI) (CA INDEX NAME)




RN 404571-33-1 CAPLUS
CN Morpholine, 4-[[4-(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-34-2 CAPLUS
CN Piperazine, 1-[[4-(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-38-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chloro-4-fluorophenyl)-5-isoxazolyl)-N-([1-ethyl-2-pyrrolidinyl]methyl)]- (9CI) (CA INDEX NAME)




RN 404571-39-7 CAPLUS
CN Morpholine, 4-[[4-(4-(3-chloro-4-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-40-0 CAPLUS
CN Piperazine, 1-[[4-(4-(3-chloro-4-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)





RN 404571-41-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-42-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 404571-43-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-54-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-55-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)


RN 404571-44-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-45-5 CAPLUS
CN Morpholine, 4-[[4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-46-6 CAPLUS
CN Piperazine, 1-[[4-[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-53-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-56-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 404571-57-9 CAPLUS
CN Morpholine, 4-[[4-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-58-0 CAPLUS
CN Piperazine, 1-[[4-[4-(3,5-dichlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 404571-59-1 CAPLUS
CN Morpholine, 4-[[4-[[4-(aminosulfonyl)-3-chlorophenyl]-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-60-4 CAPLUS
CN Morpholine, 4-[[4-[[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-61-5 CAPLUS
CN Piperazine, 1-[[4-[[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-65-9 CAPLUS
CN Isoquinoline, 2-[[4-[[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 404571-66-0 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[4-[[4-(3-methylphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-67-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[4-[[4-(3-chlorophenyl)-5-isoxazolyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-62-6 CAPLUS
CN Piperazine, 1-phenyl-4-[[4-[[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-63-7 CAPLUS
CN Piperazine, 1-[[4-[[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 404571-64-8 CAPLUS
CN Piperazine, 1-[[4-[[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 404571-68-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[4-[[4-(3-chloro-2-fluorophenyl)-5-isoxazolyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 404571-69-3 CAPLUS
CN Piperazine, 1-[[4-[[4-(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 404571-70-6 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-[[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-71-7 CAPLUS
CN Isoquinoline, 2-[[4-[(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 404571-72-8 CAPLUS
CN 3-Piperidinol, 1-[[4-[(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-73-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[4-[(3,4-dimethoxyphenyl)-5-isoxazolyl]-N-methyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 404571-77-3 CAPLUS
CN 1-Piperazineethanol, 4-[[4-[(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-78-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[[4-[(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-79-5 CAPLUS
CN 2-Piperidineethanol, 1-[[4-[(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-74-0 CAPLUS
CN 3-Piperidinol, 1-[[4-[(3-methylphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-75-1 CAPLUS
CN Piperazine, 1-[[4-[(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 404571-76-2 CAPLUS
CN Piperazine, 1-[[4-[(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-80-8 CAPLUS
CN 2-Piperidineethanol, 1-[[4-[(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-81-9 CAPLUS
CN Piperazine, 1-[[4-[(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404571-82-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[4-[(3,4-dimethoxyphenyl)-5-isoxazolyl]-N-methyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 404571-83-1 CAPLUS
CN Piperazine, 1-[[4-[(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]-4-(2-pyridinyl)]- (9CI) (CA INDEX NAME)




RN 404571-84-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-phenyl-5-isoxazolyl)-N-(2-(3-pyridinyl)ethyl)]- (9CI) (CA INDEX NAME)




RN 404571-85-3 CAPLUS
CN Morpholine, 4-[[4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)





RN 404571-89-7 CAPLUS
CN Pyrrolidine, 1-[[4-[(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-90-0 CAPLUS
CN Piperazine, 1-[[4-[(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]-4-phenyl]- (9CI) (CA INDEX NAME)




RN 404571-91-1 CAPLUS
CN Morpholine, 4-[[4-[(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404571-86-4 CAPLUS
CN Pyrrolidine, 1-[[4-[(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-87-5 CAPLUS
CN Pyridine, 4-[(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[[4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-88-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3,4-dimethoxyphenyl)-5-isoxazolyl)-N-(2-(3-pyridinyl)ethyl)]- (9CI) (CA INDEX NAME)


RN 404571-92-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-methylphenyl)-5-isoxazolyl)-N-(2-(3-pyridinyl)ethyl)]- (9CI) (CA INDEX NAME)



RN 404571-93-3 CAPLUS
CN Pyrrolidine, 1-[[4-[(4-(3-methylphenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-95-5 CAPLUS
CN Pyrrolidine, 1-[[4-[(4-(3-chloro-2-fluorophenyl)-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404571-96-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[(4-(3-chlorophenyl)-5-isoxazolyl)-N-(2-(3-pyridinyl)ethyl)]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)


RN 404572-09-4 CAPLUS
CN Piperazine, 1-[[4-[[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)



RN 404572-10-7 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-[[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]]- (9CI) (CA INDEX NAME)




RN 404572-11-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-methyl-4-[[4-(3-methylphenyl)-5-isoxazolyl]-N-(phenylmethyl)]- (9CI) (CA INDEX NAME)




RN 404572-12-9 CAPLUS
CN 2-Piperidineethanol, 1-[[4-[[4-(3-methylphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)


RN 404572-16-3 CAPLUS
CN 1H-1,4-Diazepine, 1-[[4-[[4-(3,4-dimethoxyphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]hexahydro-4-methyl]- (9CI) (CA INDEX NAME)



RN 404572-17-4 CAPLUS
CN 1H-1,4-Diazepine, 1-[[4-[[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]hexahydro-4-methyl]- (9CI) (CA INDEX NAME)




RN 404572-18-5 CAPLUS
CN 3-Piperidinol, 1-[[4-[[4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]]- (9CI) (CA INDEX NAME)




RN 404572-20-9 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-[[4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]]- (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 404572-13-0 CAPLUS
CN 2-Piperidineethanol, 1-[[4-[[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]]- (9CI) (CA INDEX NAME)




RN 404572-14-1 CAPLUS
CN 2-Piperidineethanol, 1-[[4-[[4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]]- (9CI) (CA INDEX NAME)




RN 404572-15-2 CAPLUS
CN 2-Piperidineethanol, 1-[[4-[[4-(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]]- (9CI) (CA INDEX NAME)




L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 404572-21-0 CAPLUS
CN Piperazine, 1-[[4-[[4-(3-methylphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]]- (9CI) (CA INDEX NAME)




RN 404572-22-1 CAPLUS
CN 1-Piperazineethanol, 4-[[4-[[4-(3-methylphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]]- (9CI) (CA INDEX NAME)




RN 404572-23-2 CAPLUS
CN 1,4'-Bis(piperidine, 1'-[[4-[[4-(3-methylphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]]- (9CI) (CA INDEX NAME)




RN 404572-24-3 CAPLUS
CN Pyridine,
4-[(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[[4-[(3-methylphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-25-4 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-[(3-methylphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-26-5 CAPLUS
CN 1H-1,4-Diazepine, 1-[[4-[(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]hexahydro-4-methyl-, (9CI) (CA INDEX NAME)



RN 404572-28-7 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-[(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-29-8 CAPLUS
CN Isoquinoline,
2-[[4-[(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-1,2,3,4-tetrahydro-, (9CI) (CA INDEX NAME)




RN 404572-30-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-4-(4-phenyl-5-isoxazolyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 404572-31-2 CAPLUS
CN 3-Piperidinol, 1-[[4-[(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-32-3 CAPLUS
CN Piperazine, 1-[[4-[(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 404572-33-4 CAPLUS
CN 1-Piperazineethanol, 4-[[4-[(3-chlorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404572-35-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[4-[(3-chlorophenyl)-5-isoxazolyl]-N-methyl-N-(2-(2-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 404572-36-7 CAPLUS
CN 2-Piperidineethanol, 1-[[4-[(3-methylphenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404572-38-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)-5-isoxazolyl]-N-methyl-N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 404572-39-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[[4-[(3-chloro-2-fluorophenyl)-5-isoxazolyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404572-40-3 CAPLUS
CN 4-Piperidinol, 1-[[[4-(4-phenyl-5-isoxazolyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.27	228.79
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.19	-2.19

FILE 'REGISTRY' ENTERED AT 08:53:22 ON 24 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0
DICTIONARY FILE UPDATES: 23 OCT 2005 HIGHEST RN 865836-54-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d his

(FILE 'HOME' ENTERED AT 08:45:31 ON 24 OCT 2005)

FILE 'REGISTRY' ENTERED AT 08:46:05 ON 24 OCT 2005

L1	STRUCTURE UPLOADED
L2	3 S L1
L3	377 S L1 FULL
L4	368 S L3 AND CAPLUS/LC
L5	STRUCTURE UPLOADED
L6	173 S L5 FULL SUB=L3
L7	173 S L6 AND CAPLUS/LC

FILE 'CAPLUS' ENTERED AT 08:52:59 ON 24 OCT 2005

L8 3 S L7

FILE 'REGISTRY' ENTERED AT 08:53:22 ON 24 OCT 2005

=> s l4 not l7

L9 195 L4 NOT L7

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.43	229.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.19

FILE 'CAPLUS' ENTERED AT 08:53:33 ON 24 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Oct 2005 VOL 143 ISS 18

FILE LAST UPDATED: 23 Oct 2005 (20051023/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l9

L10 60 L9

=> d ibib abs hitstr 1-3 and 57-60

'AND' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications

MAX ----- ALL, plus Patent FAM, RE
 PATS ----- PI, SO
 SAM ----- CC, SX, TI, ST, IT
 SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
 SCAN must be entered on the same line as the DISPLAY,
 e.g., D SCAN or DISPLAY SCAN)
 STD ----- BIB, IPC, and NCL

 IABS ----- ABS, indented with text labels
 IALL ----- ALL, indented with text labels
 IBIB ----- BIB, indented with text labels
 IMAX ----- MAX, indented with text labels
 ISTD ----- STD, indented with text labels

 OBIB ----- AN, plus Bibliographic Data (original)
 OIBIB ----- OBIB, indented with text labels

 SBIB ----- BIB, no citations
 SIBIB ----- IBIB, no citations

 HIT ----- Fields containing hit terms
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
 containing hit terms
 HITRN ----- HIT RN and its text modification
 HITSTR ----- HIT RN, its text modification, its CA index name, and
 its structure diagram
 HITSEQ ----- HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and
 its structure diagram
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 KWIC ----- Hit term plus 20 words on either side
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
 ENTER DISPLAY FORMAT (BIB):end

=> d ibib abs hitstr 1-3

L10 ANSWER 1 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 2005:962251 CAPLUS
 DOCUMENT NUMBER: 143:26955
 TITLE: Synthesis of polyheterocyclic compounds as
 metabotropic glutamate receptor antagonists
 INVENTOR(S): Arora, Jala; Edwards, Louise; Isaac, Methvin; Kers,
 Annika; Staaf, Karin; Slassi, Abdelmalik; Stefanac,
 Tomislav; Wensbo, David; Xin, Tao; Molm, Bjoern
 Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.
 PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080386	A1	20050901	WO 2005-US5216	20050217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DL, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.: US 2004-545292P P 20040218

GI







IT 863647-31-8P 863647-32-9P 863647-33-0P
 863647-34-1P 863647-35-2P 863647-36-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of polyheterocyclic compds., their metabotropic glutamate
 receptor antagonist activity, and use in treating mGluR5 mediated
 disorders)
 RN 863647-31-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[5-(3-chlorophenyl)-3-isoxazolyl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 863647-32-9 CAPLUS
 CN Isoxazole, 5-(3-chlorophenyl)-3-(2-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 863647-36-3 CAPLUS
 CN 1-Pyrrolidinecarboximidothioic acid,
 2-[5-(3-chlorophenyl)-3-isoxazolyl]-N-
 cyclopropyl-, methyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT



RN 863647-33-0 CAPLUS
 CN 1-Pyrrolidinecarbothioamide,
 2-[5-(3-chlorophenyl)-3-isoxazolyl]-N-methyl-
 (9CI) (CA INDEX NAME)



RN 863647-34-1 CAPLUS
 CN 1-Pyrrolidinecarbothioamide, 2-[5-(3-chlorophenyl)-3-isoxazolyl]-N-
 cyclopropyl- (9CI) (CA INDEX NAME)




RN 863647-35-2 CAPLUS
 CN 1-Pyrrolidinecarboximidothioic acid,
 2-[5-(3-chlorophenyl)-3-isoxazolyl]-N-
 methyl-, methyl ester (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2005:582509 CAPLUS
 DOCUMENT NUMBER: 143:115522
 TITLE: A method for preparing 3,4-diphenyl-substituted
 isoxazole derivatives such as valdecoxib, parecoxib,
 and their intermediates
 INVENTOR(S): Sundaram, Venkataraman; Bhimireddy, Anuradha;
 Eswaralash, Sajja; Goverdhan, Gilla; Purandhar,
 Koilkonda; Rajendra, Surasani; Raju, Nadimpally
 Satyavashala; Reddy, Anumula Raghupathi; Reddy,
 Lekkala Amarnath; Reddy, Emani Srinivasa; Reddy, Padi
 Prathap; Sampath, Alla; Sravanthi, Vecha
 Reddy's Laboratories Ltd., India; Reddy's
 Laboratories, Inc.
 SOURCE: Eur. Pat. Appl., 15 pp.
 CODEN: EPXKDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1550658	A1	20050706	EP 2004-258181	20041230
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 2005182113	A1	20050818	US 2004-25855	20041229
CA 2491332	AA	20050630	CA 2004-2491332	20041230
PRIORITY APPLN. INFO.:			IN 2003-CH1063	A 20031230
			US 2004-591799P	P 20040728
			US 2004-637782P	P 20041221

OTHER SOURCE(S): MARPAT 143:115522
 GI




AB The invention relates to a process for preparing 3,4-diphenyl-substituted
 isoxazole derivs. of formula I [wherein: X is H, SO₂-alkyl, SO₂NH₂, or
 alkanoylamino-SO₂] such as valdecoxib, parecoxib, and their
 intermediates.
 For instance, 3,4-diphenyl-5-methylisoxazole (I, X is absent) was
 prepared
 via one-pot cyclocondensation of benzonitrile oxide with
 1-(1-methyl-2-phenylethenyl)pyrrolidine and subsequent pyrrolidine
 removal

L10 ANSWER 2 OF 60 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 of the obtained 3,4-diphenyl-5-methyl-5-pyrrolidinylisoxazoline with a
 yield of 22.2%.

IT 857259-65-5P
 RL: IMP (Industrial manufacture); RCT (Reactant); SPN (Synthetic
 preparation); PREP (Preparation); RACT (Reactant or reagent)
 (method for preparing 3,4-diphenyl-substituted isoxazole derivs. such
 as valdecoxib, parecoxib, and their intermediates)

RN 857259-65-5 CAPLUS
 CN isoxazole, 4,5-dihydro-5-methyl-3,4-diphenyl-5-(1-pyrrolidinyl)- (9CI)
 (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L10 ANSWER 3 OF 60 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 2005:395305 CAPLUS
 DOCUMENT NUMBER: 142:463737
 TITLE: Preparation of 4-(pyrazol-3-ylamino)pyrimidines for
 use in the treatment of cancer
 INVENTOR(S): Nowak, Thorsten; Thomas, Andrew Peter
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 272 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040159	A1	20050506	WO 2004-GB4307	20041011

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, GR, GU, HD, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-24335 A 20031017
 GB 2004-12194 A 20040602

OTHER SOURCE(S): MARPAT 142:463737
 GI



L10 ANSWER 3 OF 60 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

AB The title compds. I (R1 = CF3, alkyl, cycloalkyl, (cycloalkyl)alkyl; R2 =
 H, halo, CF3; R3 = H, OH, halo, etc.; NQ1 = N-linked saturated
 monocyclic 5-6
 membered ring containing one N heteroatom and optionally comprising one
 or
 more addnl. ring heteroatoms selected from N, O and S; Q2 =
 (un)substituted 5-6 membered heteroaryl comprising at least one ring
 heteroatom selected from N, O and S], useful in modulating insulin-like
 growth factor 1 receptor activity in a warm blooded animal such as man,
 were prepared. Thus, reacting 2,5-dichloro-4-(5-methyl-1H-pyrazol-3-
 yl)amino)pyrimidine with 2-[3-(pyridin-2-yl)isoxazol-5-yl]pyrrolidine
 (preparation given) in the presence EtN(iiso-Pr)2 in n-hexanol afforded


II. HCl.

The compds. I of the examples were found to have an IC50 of <100 µM in
 IGF-1R kinase assay. The pharmaceutical composition comprising the
 compound I is
 disclosed.


IT 851432-02-5P 851432-03-6P 851432-09-2P
 851432-10-5P 851433-96-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(Preparation of 4-(pyrazol-3-ylamino)pyrimidines for use in the
 treatment of
 Cancer)

RN 851432-02-5 CAPLUS
 CN 4-Pyrimidinamine, 5-chloro-2-[2-(3-cyclopropyl-5-isoxazolyl)-1-
 pyrrolidinyl]-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 851432-03-6 CAPLUS
 CN 4-Pyrimidinamine, 5-chloro-2-[2-(3-cyclopropyl-5-isoxazolyl)-1-
 pyrrolidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 851432-09-2 CAPLUS

L10 ANSWER 3 OF 60 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 CN 4-Pyrimidinamine, 2-[2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl]-N-(5-
 (methoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 851432-10-5 CAPLUS
 CN 4-Pyrimidinamine, 2-[2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl]-N-(5-
 cyclopropyl-1H-pyrazol-3-yl)-6-(methoxymethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 851433-96-0 CAPLUS
 CN 4-Pyrimidinamine, 2-[2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl]-N-(5-
 (5-cyclopropyl-1H-pyrazol-3-yl)-6-(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 IT 851434-83-8P, 2-(3-Cyclopropylisoxazol-5-yl)pyrrolidine
 851434-90-7P 851434-91-8P, 2-[2-(3-Cyclopropylisoxazol-5-
 yl)pyrrolidin-1-yl]-4-hydroxy-6-methoxymethylpyrimidine


L10 ANSWER 3 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 851434-92-9F, 4-Chloro-2-[2-(3-cyclopropylisoxazol-5-yl)pyrrolidin-1-yl]-6-methoxymethylpyrimidine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of 4-(pyrazol-3-ylamino)pyrimidines for use in the treatment of cancer)
 RN 851434-83-8 CAPLUS
 CN . Isoxazole, 3-cyclopropyl-5-(2-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 851434-90-7 CAPLUS
 CN 1-Pyrrolidinecarboximidamide, 2-(3-cyclopropyl-5-isoxazolyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 851434-89-4
 CMF C11 H16 N4 O




CM 2

CRN 7664-93-9
 CMF H2 O4 S




RN 851434-91-8 CAPLUS
 CN 4(1H)-Pyrimidinone, 2-[2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl]-6-(methoxymethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 851434-92-9 CAPLUS
 CN Pyrimidine, 4-chloro-2-[2-(3-cyclopropyl-5-isoxazolyl)-1-pyrrolidinyl]-6-(methoxymethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


=> d ibib abs hitstr 57-60

L10 ANSWER 57 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1966:438483 CAPLUS
 DOCUMENT NUMBER: 65:38483
 ORIGINAL REFERENCE NO.: 65:7160g-h, 7161a-d
 TITLE: Convenient synthesis of indoxazenes
 AUTHOR(S): Bianchi, Giorgio; Frati, Enzo
 CORPORATE SOURCE: Univ. Pavia
 SOURCE: Gazzetta Chimica Italiana (1966), 96(5), 559-65
 CODEN: GCITA9; ISSN: 0016-5603
 DOCUMENT TYPE: Journal
 LANGUAGE: Italian
 GI For diagram(s), see printed CA Issue.
 AB 3-Aryltetrahydroindoxazenes, obtained by the condensation of the appropriate nitrile oxides with suitable cyclohexanone enamines and subsequent treatment with acids, were dehydrogenated with N-bromosuccinimide to the corresponding 3-aryloxindoxazenes (I). 3-Phenyl-naphtho[2,1-d]isoxazole (II) and the [1,2-d]-isomer were also prepared in this manner. α -Tetralone condensed with pyrrolidine yielded 18 β -1-pyrrolidino-3,4-dihydronaphthalene, b.p. 25, 102-4°. m-O₂NC₆H₄CN(O), m. 82-3°, was prepared from m-O₂NC₆H₄C(:NOH)OH with 1 mole equivalent NaOEt. The appropriate nitrile oxide and enamine (equimolar amts.) in Et₂O refluxed 2 hrs. yielded the corresponding IV (X = morpholino or pyrrolidino) which were also obtained by adding dropwise with cooling the appropriate arylbenzhydroxamyl chloride (V) in Et₂O to equimolar amts. enamine and Et₃N or by treating the V in Et₂O with 1 equivalent enamine. The following compds. were prepared by these methods (m.p., λ_{max} in m μ , and log ϵ given): IV (Ar = Ph, R = H, X = morpholino), 91-2° (iso-Pr₂O), 264, 4.10; IV (Ar = m-O₂NC₆H₄, R = H, X = pyrrolidino), 96-7° (EtOH), 260, 4.26; IV (Ar = Ph, R = Me, X = pyrrolidino), 88-9° (petroleum ether), 264, 4.08; VI (X = pyrrolidino) (VII), 148° (MeOH), 264, 4.16; VIII (X = morpholino) (IX), 241° (AcOEt or PhNO₂), 256, 4.02. The appropriate IV and VII and IX refluxed 1-2 hrs. with 10% H₂SO₄ yielded 50-90% of the following compds. (same data given): IVa (Ar = m-O₂NC₆H₄, R = H), 126° (EtOH), 230, 4.30; VIa (Ar = Ph, R = Me), 60° (MeOH), 240, 4.09; X, 112° (MeOH), 222 (285, 300), 4.39 (4.22, 4.12); XI, 88° (MeOH), 257, 4.04. The appropriate IVa and X and XI (0.02 mole) in CCl₄ treated with 0.04, 0.02, and 0.02 mole equivs. N-bromosuccinimide and a trace [Me₂C(CN)N]₂, refluxed, treated with AcONa in the presence of AcOH or with KOH-MeOH yielded the following compds. (% yield and m.p. given):
 I (Ar = Ph, R = H), 53, 82.5°; I (Ar = m-O₂NC₆H₄, R = H) (XII), 90, 171-2° (C₆H₆); I (Ar = Ph, R = Me), --, 92-3° (MeOH); II, 67, 133° (MeOH); III, 92, 62-3° (petroleum ether). In the preparation of XII, the intermediary yellow 3-(3-nitrophenyl)-4,7-dibromo-4,5,6,7-tetrahydroindoxazene, m. 154-5°, could be isolated in 70% yield. III in 95% EtOH hydrogenated over Raney Ni, and the crude product heated 20 min. with 50% H₂SO₄ yielded 91% yellow 1-benzoyl-2-naphthol, m. 66° (petroleum ether).
 IT 7007-73-0, Naphth[2,1-d]isoxazole, 3a,4,5,9b-tetrahydro-3-phenyl-9b-(1-pyrrolidinyl)- 7007-74-1, 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-5-methyl-3-phenyl-7a-(1-pyrrolidinyl)- 7007-75-2, 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-3-(m-nitrophenyl)-7a-(1-pyrrolidinyl)- (preparation of)
 RN 7007-73-0 CAPLUS
 CN Naphth[2,1-d]isoxazole, 3a,4,5,9b-tetrahydro-3-phenyl-9b-(1-pyrrolidinyl)-

L10 ANSWER 58 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1964:418213 CAPLUS
 DOCUMENT NUMBER: 61:18213
 ORIGINAL REFERENCE NO.: 61:3089c-e
 TITLE: Enamines as 1,3-dipolarophiles
 AUTHOR(S): Kuehne, Martin E.; Weaver, J.; Franz, Peter
 CORPORATE SOURCE: Univ. of Vermont, Burlington
 SOURCE: Journal of Organic Chemistry (1964), 29(6), 1582-6
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 61:18213
 GI For diagram(s), see printed CA Issue.
 AB The reactions of benzhydroxamyl chloride and N1- α -chlorobenzylidene-N2-phenylhydrazine with cyclic and acyclic enamines led to aminodihydroisoxazoles e.g. I, and a pyrrolidinodihydropyrazole (II). Elimination of the tertiary amine from the substituted heterocycles gave the corresponding isoxazoles, e.g. III; tetrahydroisindazoles, e.g. IV, were obtained directly, except in the case of the reaction leading first to II. Pyrazoles were also obtained.
 IT 95867-96-2, 2-Isoxazoline, 3,4,5-triphenyl-5-(1-pyrrolidinyl)- 97847-70-6, 4H-Cyclopent[d]isoxazole, 3a,5,6,6a-tetrahydro-3-phenyl-6a-(1-pyrrolidinyl)- 98563-49-6, 4H-Cyclohept[d]isoxazole, 3a,5,6,7,8a-hexahydro-3-phenyl-8a-(1-pyrrolidinyl)- (preparation of)
 RN 95867-96-2 CAPLUS
 CN 2-Isoxazoline, 3,4,5-triphenyl-5-(1-pyrrolidinyl)- (7CI) (CA INDEX NAME)





RN 97847-70-6 CAPLUS
 CN 4H-Cyclopent[d]isoxazole, 3a,5,6,6a-tetrahydro-3-phenyl-6a-(1-pyrrolidinyl)- (7CI, 9CI) (CA INDEX NAME)




RN 98563-49-6 CAPLUS
 CN 4H-Cyclohept[d]isoxazole, 3a,5,6,7,8a-hexahydro-3-phenyl-8a-(1-pyrrolidinyl)- (7CI) (CA INDEX NAME)


L10 ANSWER 57 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (7CI, 8CI) (CA INDEX NAME)




RN 7007-74-1 CAPLUS
 CN 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-5-methyl-3-phenyl-7a-(1-pyrrolidinyl)- (7CI, 8CI) (CA INDEX NAME)



RN 7007-75-2 CAPLUS
 CN 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-3-(m-nitrophenyl)-7a-(1-pyrrolidinyl)- (7CI, 8CI) (CA INDEX NAME)




L10 ANSWER 58 OF 60 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




L10 ANSWER 59 OF 60 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 1964:418212 CAPLUS
 DOCUMENT NUMBER: 61:18212
 ORIGINAL REFERENCE NO.: 61:3088e-h,3089a-c
 TITLE: 2,2'-Dicarbamoyl-5,5'-dinitrodiphenyl disulfides and 6-nitro-1,2-benzisothiazolones
 AUTHOR(S): Ponci, R.; Gialdi, F.; Baruffini, A.
 CORPORATE SOURCE: Univ. Pavia, Italy
 SOURCE: Farmaco, Editrice Scientifica (1964), 19(3), 254-68
 CODEN: FRPSAX; ISSN: 0430-0920
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 61:18212
 GI For diagram(s), see printed CR issue.
 AB A solution of 16 g. 2-thiocyanato-4-nitrobenzoic acid (prepared from 4-nitroanthranilic acid by the Sandmeyer reaction) in 300 ml. 20% KOH was kept on a water bath gradually heated during 30 min. to 90°, heated 30 min. at 90°, cooled, acidified with concentrated HCl, and chilled to precipitate yellow 2-mercapto-4-nitrobenzoic acid (I); S-benzyl derivative, yellow, m. 197-9° (dilute EtOH, C6H6). To the moist I dissolved in hot EtOH was added an equal volume cold EtOH and half volume 10% H2SO4, the mixture treated dropwise with 5% iodine-EtOH to complete oxidation an equal volume dilute H2SO4 added, and the whole chilled 24 hrs., filtered off, and the solid washed with EtOH, Et2O, and petr. ether to give 70% 2,2'-dicarboxy-5,5'-dinitrodiphenyl disulfide (II), yellow, m. 280-2° (glacial AcOH). To a suspension of 20 g. dry II in 140 ml. anhydrous C6H6, 25 g. PCl5 was added, the mixture refluxed 1 hr., decolorized with C, filtered, 4 vols. petr. ether added, the mixture kept a long time at 0°, filtered off, and the solid washed with petr. ether and crystallized from C6H6-petr. ether to yield 2,2'-dicarboxy-5,5'-dinitrodiphenyl disulfide dichloride (III), yellow, m. 170-1°. III (2.16 g.) in min. cold dioxane was added dropwise to a solution of 2 ml. concentrated NH3 in 13 ml. dioxane, the mixture kept 15 min. at room temperature, 3 vols. H2O added, the mixture neutralized with AcOH, and the precipitate filtered off, and washed with H2O, then EtOH and Et2O to yield 2,2'-dicarbamoyl-5,5'-dinitrodiphenyl disulfide (IV), yellow, m. 265-6° (AcOH). III analogously treated with BuNH2 and PhNH2 yielded, resp., 2,2'-bis(N-butylcarbamoyl)-5,5'-dinitrodiphenyl disulfide (V) pale yellow, m. 227-9° (AcOH), and 2,2'-dicarbanilino-5,5'-dinitrodiphenyl disulfide (VI), pale yellow, m. 270-1° (PhNO2). Through a suspension of 4.3 g. III in 60 ml. anhydrous CCl4 containing 0.2 g. iodine, anhydrous Cl was bubbled to complete dissoln., excess Cl removed by bubbling dry air, the solution, containing 4,2-O2N(C1S)C6H3COCl (VII), added dropwise, with stirring and cooling, to 12 ml. 20% aqueous NH3, the mixture kept 2 hrs. at room temperature, the precipitate filtered off, washed with petr. ether, and suspended in a little H2O, the mixture acidified with dilute HCl, and the precipitate filtered off and washed with H2O to yield 6-nitro-1,2-benzisothiazolone (VIII), yellow, m. 280° (EtOH) (decomposition). VII (from 4.3 g. III) in anhydrous CCl4 was added dropwise to a solution of 5 g. BuNH2 in 20 ml.

L10 ANSWER 59 OF 60 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 anhyd. CCl4, the mixt. kept 1 hr., filtered, and the filtrate evapd. in vacuo at 40° to yield 2-butyl-6-nitro-1,2-benzisothiazolone (IX), yellow, m. 109-10° (C6H6-ligroine). VII analogously treated with PhNH2 yielded 2-phenyl-6-nitro-1,2-benzisothiazolone (X), yellow, m. 229-31° (PhMe). VIII (1 g.) suspended in 10 ml. AcOH, 3 ml. 30% H2O2 added, and the mixt. heated on a water bath 1 hr. at 100° and evapd. to dryness in vacuo at 40°, yielded 6-nitro-1,2-benzisothiazolone 1,1-dioxide m. 208-9° (H2O). In the same way IX yielded 2-butyl-6-nitro-1,2-benzisothiazolone 1,1-dioxide, m. 96-7° (70% EtOH), and X yielded 2-phenyl-6-nitro-1,2-benzisothiazolone 1,1-dioxide (XI), m. 183° (dil. EtOH). Dry pulverized VIII (2 g.) in 10 ml. AcOH was heated on a water bath 1 hr. at 100°, cooled, 5 vols. H2O added, and the ppt. filtered off and washed with H2O to yield 2-acetyl-6-nitro-1,2-benzisothiazolone, yellow, m. 220-2° (Me2CO). VIII (2 g.) treated in the same way with 10 ml. (EtCO)2O, gave 2-propionyl-6-nitro-1,2-benzisothiazolone, yellow, m. 185-6° (CHCl3). VIII in 10% alc. suspension was treated, with stirring and warming at 50° with an equimolar amt. 4N NaOH to give VIII Na salt, 2 g. of which was suspended in 30 ml. anhyd. C6H6, 1.3 g. BzCl added, the mixt. refluxed with stirring 1 hr., evapd. to dryness, and worked up to yield 2-benzoyl-6-nitro-1,2-benzisothiazolone, yellow, m. 154-6° (PhMe). V, IX, and X inhibited the growth of Trichophyton mentagrophytes at a concn. of 0.5 γ/ml. 7 references.
 IT 92647-93-3, 2-Isioxazoline, 4-ethyl-3-phenyl-5-(1-pyrrolidinyl)-
 93947-42-3, 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-7-methyl-3-phenyl-7a-(1-pyrrolidinyl)- 94803-44-8, 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-3-phenyl-7a-(1-pyrrolidinyl)- 95867-96-2, 2-Isioxazoline, 3,4,5-triphenyl-5-(1-pyrrolidinyl)- 97847-70-6, 4H-Cyclopent[d]isoxazole, 3a,5,6,6a-tetrahydro-3-phenyl-6a-(1-pyrrolidinyl)- 98563-49-6, 4H-Cyclohept[d]isoxazole, 3a,5,6,7,8,8a-hexahydro-3-phenyl-8a-(1-pyrrolidinyl)- (preparation of)
 RN 92647-93-3 CAPLUS
 CN 2-Isioxazoline, 4-ethyl-3-phenyl-5-(1-pyrrolidinyl)- (7CI) (CA INDEX NAME)




RN 93947-42-3 CAPLUS
 CN 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-7-methyl-3-phenyl-7a-(1-pyrrolidinyl)- (7CI) (CA INDEX NAME)


L10 ANSWER 59 OF 60 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 94803-44-8 CAPLUS
 CN 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-3-phenyl-7a-(1-pyrrolidinyl)- (7CI, 9CI) (CA INDEX NAME)



RN 95867-96-2 CAPLUS
 CN 2-Isioxazoline, 3,4,5-triphenyl-5-(1-pyrrolidinyl)- (7CI) (CA INDEX NAME)




RN 97847-70-6 CAPLUS
 CN 4H-Cyclopent[d]isoxazole, 3a,5,6,6a-tetrahydro-3-phenyl-6a-(1-pyrrolidinyl)- (7CI, 9CI) (CA INDEX NAME)




RN 98563-49-6 CAPLUS
 CN 4H-Cyclohept[d]isoxazole, 3a,5,6,7,8,8a-hexahydro-3-phenyl-8a-(1-pyrrolidinyl)- (7CI) (CA INDEX NAME)

L10 ANSWER 59 OF 60 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



ACCESSION NUMBER: 1964:82853 CAPLUS
 DOCUMENT NUMBER: 60:82853
 ORIGINAL REFERENCE NO.: 60:14501e-h
 TITLE: Enamines. X. Reactions of halohydroxamic acids with enamines of alicyclic compounds
 AUTHOR(S): Bianchetti, Giuseppe; Pocar, Donato; Dalla Croce, Piero
 CORPORATE SOURCE: Univ. Milan
 SOURCE: Gazzetta Chimica Italiana (1963), 93(12), 1726-35
 CODEN: GCITA9; ISSN: 0016-5603
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 60:82853
 AB 1-(N-morpholinyl)-1-cycloheptene, b13 134°, was prepared by azeotropic removal of H₂O from equimolar amts. of cycloheptanone and morpholine in PhMe containing a trace of MeC₆H₄SO₃H, followed by distillation
 Similarly was prepared 1-(N-4-methylpiperazinyl)-1-cyclopentene, b0.15 116-18°. Equimolar amts. of II, 1-(N-morpholinyl)-1-cyclohexene, and Et₃N boiled in CHCl₃ 1 hr. and evaporated to an oil that solidified
 gave V (R = 4-O₂NC₆H₄, n = 4, R' = N-morpholinyl), m. 138-40° (EtOH). Likewise, by boiling 45 min. to 1 hr. and using the resp. reagents were prepared the following derivs. of V: (R = 4-O₂NC₆H₄, R' = N-morpholinyl, n = 5), m. 180° (MeOH); (R = Ph, R' = N-pyrrolidinyl, n = 4), m. 103°; (R = 4-O₂NC₆H₄, R' = N-morpholinyl, n = 3), m. 154° (EtOH); (R = 4-ClC₆H₄, R' = N-morpholinyl, n = 3), m. 115° (MeOH); (R = Ph, R' = N-morpholinyl, n = 3), m. 105-6° (ligroine); (R = 4-ClC₆H₄, R' = N-piperidinyl, n = 3), m. 108° (EtOH); (R = 4-ClC₆H₄, R' = N-4-methylpiperidinyl, n = 3), m. 120° (ligroine). Also prepared was 3-(4-nitrophenyl)8a-(N-morpholinyl)-3a,8a-dihydroindenol[1,2-d]isoxazole (in absence of Et₃N), m. 238° (EtOH). Derivs. of V with n = 4 or 5 were readily hydrolyzed by 10-20% HCl to the corresponding derivs. of VI; thus were prepared: R = 4-O₂NC₆H₄, n = 4, m. 180° (EtOH); R = 4-O₂NC₆H₄, n = 5, m. 132° (MeOH); R = Ph, n = 4, m. 50° (aqueous AcOH); however V with n = 3 were recovered unchanged even with 48% HBr. V (R = Ph, R' = N-morpholinyl, n = 4), m. 103°, was also prepared as in previous paper from benzonitrile N-oxide and 1-(N-morpholinyl)-1-cyclohexene (VII) in boiling CHCl₃, 30 min. VI (R = CO₂H, n = 4), m. 128° (H₂O), was prepared by boiling 10 g. ClC(:NOH)(CO₂Et) and VII in 300 cc. CHCl₃ 1 hr. and evaporating to an oil which was extracted with Et₂O, filtered, evaporated, and the residue boiled 30 min. with 100 cc. 10% NaOH and then acidified.
 IT 94803-44-8, 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-3-phenyl-7a-(1-pyrrolidinyl)- (preparation of)
 RN 94803-44-8 CAPLUS
 CN 1,2-Benzisoxazole, 3a,4,5,6,7,7a-hexahydro-3-phenyl-7a-(1-pyrrolidinyl)- (7CI, 9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

35.03

264.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.11

-7.30

STN INTERNATIONAL LOGOFF AT 08:54:08 ON 24 OCT 2005